Inactive Instrument

Catalyst Biosciences Inc Nasdaq

Equities

US87611R3066

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2023	Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	CI
2023	Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	CI

Targacept , Inc. : Targacept to Present at the 30th Annual J.P. Morgan Healthcare Conference

January 04, 2012 at 02:00 pm

MarketScreener.com By

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the 30^th Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco on Thursday, January 12, 2012 at 8:30 a.m. Pacific Time.

The presentation will be webcast and accessible from the Investor Relations page of Targacept's website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Investor Calendar section of the Investor Relations page of Targacept's website for at least two weeks following the event.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics^TM for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept's clinical pipeline includes five mid to late-stage product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad^TM to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.

TARGACEPT

Building Health, Restoring Independence^®

Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
alan.musso@targacept.com
or
Linnden Communications
Michelle Linn, 508-362-3087
linnmich@comcast.net

Latest news about Catalyst Biosciences Inc

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	30/10/23	CI
Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	29/10/23	CI
Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.	29/10/23	CI
Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.	26/10/23	CI
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23	CI
Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc	29/08/23	CI
North American Morning Briefing : China Trouble Hits Sentiment	18/08/23	DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders	25/07/23	MT
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
North American Morning Briefing : Hopes Build for -3-	15/05/23	DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
North American Morning Briefing : Stocks Seen -2-	30/03/23	DJ
Catalyst Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	29/03/23	CI
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	01/03/23	MT
Wider-Than-Expected Trade in Goods Deficit Kicks Off Tuesday's Data Dump, Stifling US Equity Futures	28/02/23	MT
Top Premarket Gainers	28/02/23	MT
Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer	19/01/23	CI
Top Premarket Decliners	13/01/23	MT
GNI to Take Controlling Stake in Nasdaq-listed Catalyst Biosciences via Liver Fibrosis Drug Development Deals; Shares Up 3%	28/12/22	MT
Sector Update: Health Care Edging Higher at Tuesday Close	27/12/22	MT
Sector Update: Health Care Stocks Still Struggling for Direction	27/12/22	MT
Sector Update: Health Care	27/12/22	MT
Catalyst Biosciences Acquires F351, Controlling Interest in Continent From GNI Group	27/12/22	MT
Transcript : Catalyst Biosciences, Inc., GNI Group Ltd. - Special Call	27/12/22

Chart Catalyst Biosciences Inc

Duration

Period

More charts

Company Profile

Catalyst Biosciences, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetic (PK), safety and tolerability data of single and multiple ascending doses of Hydronidone in United States healthy subjects. Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit both p38y kinase activity and TGF-b1- induced excessive collagen synthesis in vitro in hepatic stellate cells (HSCs), which are recognized as critical events in the development and progression of fibrosis in the liver.

Sector

More about the company